Dexamethasone is effective in male subjects < 70 years that require invasive mechanical ventilation experiencing symptoms from >7 days and There are no data to support the use of systemic corticosteroids in nonhospitalized patients with COVID-19
BMJ 2020;370:m3379
Selected Descriptive Patient Characteristics and Frequency of Outcomes a View Large Table 2
To evaluate the effects of dexamethasone in patients hospitalized with COVID-19
Dexamethasone has been highlighted as an effective medicine against severe coronavirus disease 2019 (COVID-19) since the early stages of the pandemic
A simple alternative would be to increase the dose of dexamethasone
The coronavirus disease 2019 (COVID-19) caused by infection of the severe respiratory syndrome coronavirus-2 (SARS-CoV-2) significantly impacted human society
More than half a billion doses of COVID-19 vaccines have now been administered in the U
Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and
DEX 6 mg IV or PO once daily plus SOC for up to 10 days or until discharge (n = 2,104) COVIDICUS: RCT of High-Dose Dexamethasone Versus Standard of Care Dexamethasone in Patients With COVID-19–Related Respiratory Failure in the ICU in
ObjectiveTo assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia
Learn about the therapeutic management of hospitalized and nonhospitalized adults with COVID-19
Only 1% of survivors developed a secondary bacterial infection, yet the median duration of fever in survivors was 12 days and cough persisted for 19 days
According to the results of a randomized trial, low-dose dexamethasone saves the lives of COVID-19 patients with severe pneumonia, reducing the chance of death by a third for those on ventilators and by a fifth for those on oxygen therapy
About 2,100 patients received a 6mg daily dose of dexamethasone in the trial for 10 days
NICE guideline [NG159] Published: 20 March 2020 Last updated: 12 February 2021
In the international, blinded COVID STEROID 2 trial, which evaluated 12 mg versus 6 mg doses of dexamethasone in patients with COVID-19 and severe hypoxaemia, Munch and colleagues and Granholm and colleagues found that mortality at 28, 90, and 180 days was five
KEYWORDS (MeSH terms): Dexamethasone, COVID-19, SARS-CoV-2, Meta-analysis [publication type], For each RCT, sample details, covariates analyzed, dosage and duration of dexamethasone treatment were extracted